Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

NCT06712927 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Brain Metastases

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab + Relatlimab FDC

Sponsor

Stanford University